Design, synthesis, and evaluation of novel (E)‐ N '‐(3‐allyl‐2‐hydroxy)benzylidene‐2‐(4‐oxoquinazolin‐3(4 H )‐yl)acetohydrazides as antitumor agents
- 21 October 2021
- journal article
- research article
- Published by Wiley in Archiv der Pharmazie
- Vol. 355 (1), e2100216
- https://doi.org/10.1002/ardp.202100216
Abstract
In our continuing search for novel small-molecule anticancer agents, we designed and synthesized a series of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides (5), focusing on the modification of substitution in the quinazolin-4(3H)-one moiety. The biological evaluation showed that all 13 designed and synthesized compounds displayed significant cytotoxicity against three human cancer cell lines (SW620, colon cancer; PC-3, prostate cancer; NCI-H23, lung cancer). The most potent compound 5l displayed cytotoxicity up to 213-fold more potent than 5-fluorouracil and 87-fold more potent than PAC-1, the first procaspase-activating compound. Structure–activity relationship analysis revealed that substitution of either electron-withdrawing or electron-releasing groups at positions 6 or 7 on the quinazolin-4(3H)-4-one moiety increased the cytotoxicity of the compounds, but substitution at position 6 seemed to be more favorable. In the caspase activation assay, compound 5l was found to activate the caspase activity by 291% in comparison to PAC-1, which was used as a control. Further docking simulation also revealed that this compound may be a potent allosteric inhibitor of procaspase-3 through chelation of the inhibitory zinc ion. Physicochemical and ADMET calculations for 5l provided useful information of its suitable absorption profile and some toxicological effects that need further optimization to be developed as a promising anticancer agent.Keywords
Funding Information
- National Research Foundation (2017R1A5A2015541)
- National Foundation for Science and Technology Development (104.01‐2019.300)
This publication has 40 references indexed in Scilit:
- Aroylhydrazone derivative as fluorescent sensor for highly selective recognition of Zn2+ ions: syntheses, characterization, crystal structures and spectroscopic propertiesDalton Transactions, 2011
- PAC-1 Activates Procaspase-3 in Vitro through Relief of Zinc-Mediated InhibitionJournal of Molecular Biology, 2009
- Targeting apoptosis: selected anticancer strategiesNature Reviews Drug Discovery, 2008
- Physiochemical drug properties associated with in vivo toxicological outcomesBioorganic & Medicinal Chemistry Letters, 2008
- Components of the Cell Death Machine and Drug Sensitivity of the National Cancer Institute Cell Line PanelClinical Cancer Research, 2004
- UCSF Chimera?A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Increased expression of Apaf-1 and procaspase-3 and the functionality of intrinsic apoptosis apparatus in non-small cell lung carcinomaBiological Chemistry, 2004
- Characterization of the Interleukin-1β-Converting Enzyme/Ced-3-Family Protease, Caspase-3/CPP32, in Hodgkin's Disease: Lack of Caspase-3 Expression in Nodular Lymphocyte Predominance Hodgkin's DiseaseThe American Journal of Pathology, 1999
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990